Navigation Links
Moleac Announces Breakthrough Results on Neuroprotective and Neurogenerative Properties of NeuroAiD
Date:2/11/2010

SINGAPORE, Feb. 11 /PRNewswire-Asia/ -- The January issue of "Neuropharmacology", publishes the article entitled "Neuroprotective and Neuroproliferative Activities of NeuroAiD", reporting pharmacological data establishing NeuroAiD (MLC 601) protective effects on neuronal and brain injuries as well as its effectiveness in neurological functions recovery.

The French research team was led by Prof. Michel Lazdunski, world-renowned specialist of pharmacology.

The data demonstrates NeuroAiD effects on decreasing cognitive deficits, preventing death of threatened neuronal tissues and improving functional outcomes by repairing and restoring neuronal circuits. This is fully consistent with clinical observations of NeuroAiD efficacy as a post stroke treatment.

NeuroAiD treatment increases survival rate, reduces infarct volume, prevents neuronal death and drastically decreases functional deficits in rodents' stroke models. The data also shows NeuroAiD effectiveness in reducing stroke severity when administrated preventively.

The results show that NeuroAiD triggers the synthesis of Brain Derived Neurotrophic Factor (BDNF), which is known to promote neuroplasticity. Indeed NeuroAiD induces neurogenesis in rodent and human cells, and stimulates the development of new neuronal circuits of information.

Previous trials and clinical reports conducted in Asia have already demonstrated high levels of NeuroAiD safety and efficacy in improving stroke rehabilitation, even when taken several months after stroke onset. NeuroAiD Stroke Treatment is already available in many countries in Asia and in the Middle East for stroke survivors. New clinical assessments will be conducted in France and Europe shortly on stroke recovery.

David Picard, CEO of Moleac, said "We are extremely enthusiastic and proud to see these data published. It is a strong validation of our research of active ingredients in NeuroAiD as well as of our efforts towards continuous optimization of its formula. These results pave the way for new indications of NeuroAiD beyond stroke recovery such as prevention, cognitive impairments and dementia. It is good news for patients who are in need of treatment in this under-served therapeutic area."

About Moleac

Moleac is a Singapore-based biopharmaceutical company that dedicates itself in finding and developing new medicines for the unmet needs of patients worldwide. http://www.moleac.net

About NeuroAiD

NeuroAiD is a stroke treatment to help stroke patients achieve faster and better recovery. NeuroAiD is derived from natural components, carefully selected for their efficacy and absence of side effects. It currently reaches out to patients in over 25 countries. http://www.neuroaid.com

    Contact details:

     Kasia Kaminska
     Tel: +65-64789432
     Kasia.kaminska@moleac.net

SOURCE Moleac

RELATED LINKS
http://www.moleac.net
http://www.neuroaid.com

'/>"/>

SOURCE Moleac
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Moleac Named Singapore Entrepreneurial Company of the Year at the Frost & Sullivan Excellence in Healthcare Awards
2. Moleac Launches NeuroAid10(TM) in the United States
3. Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing
4. Kinexus Announces the Launch of a New Protein Kinase Microarray
5. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
6. Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results
7. Silicon Kinetics Announces New Biosensor Chips With Wide Palette of Surface Chemistries
8. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
9. Healthcare Data Solutions Announces Expansion of its Healthcare Customer Solutions Team With Two Key Additions
10. Angiotech Pharmaceuticals Announces Conference Call and Webcast
11. Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... The report "Direct-Fed Microbials Market by Type (Lactic Acid Bacteria and Bacillus), Livestock ... Global Forecast to 2022", published by MarketsandMarkets, the global market is estimated to ... 1,399.6 Million by 2022, at a CAGR of 6.96% from 2016. ... ... MarketsandMarkets Logo ...
(Date:1/11/2017)... ... 11, 2017 , ... Ovation Fertility™ Genetics now offers a ... screening (PGS). , “Our genetics and IVF teams are recognized experts in both ... Amy Jones, M.S., ELD (ABB) , who has worked with or directed ...
(Date:1/11/2017)... , Jan. 11, 2017  Brian Mehling, M.D., world-renowned ... of Blue Horizon International (BHI), will be attending the ... Davos from January 17-20, 2017. This will ... The theme of this year,s forum is ... 400 sessions will address strategies for fostering greater social ...
(Date:1/11/2017)... San Francisco, CA (PRWEB) , ... January 11, ... ... ongoing series of in-kind scientific grants to ground-breaking microbiome studies. Its most recent ... University School of Medicine, who will study the effect of long-term use of ...
Breaking Biology Technology:
(Date:12/15/2016)... , Dec. 15, 2016  There is much ... doors or starting the engine. Continental will demonstrate the ... Las Vegas . Through the combination of ... and Entry) and biometric elements, the international technology company ... vehicle personalization and authentication. "The integration of ...
(Date:12/8/2016)...  Singulex, Inc., the leader in Next Generation Immunodiagnostics ... license and supply agreement with Thermo Fisher Scientific, the ... access to Thermo Scientific BRAHMS PCT (Procalcitonin), a biomarker ... to diagnose systemic bacterial infection and sepsis and in ... in assessing the risk of critically ill patients for ...
(Date:12/7/2016)... 7, 2016   Veridium , a leader ... of new CEO James Stickland . Stickland, ... of experience, has served in senior executive roles ... specialized in expanding a pipeline of venture capital ... most recently served as managing director of U.K.-based ...
Breaking Biology News(10 mins):